PDGFBB promotes proliferation and migration via regulating miR-1181/STAT3 axis in human pulmonary arterial smooth muscle cells.
Zhengjiang QianYanjiao LiHaiyang YangJidong ChenXiang LiDeming GouPublished in: American journal of physiology. Lung cellular and molecular physiology (2018)
Platelet-derived growth factor (PDGF) can induce hyperproliferation of pulmonary artery smooth muscle cells (PASMCs), which is a key causative factor to the occurrence and progression of pulmonary arterial hypertension (PAH). We previously identified that miR-1181 is significantly downregulated by PDGFBB in human PASMCs. In this work, we further explore the function of miR-1181 and underlying regulatory mechanisms in PDGF-induced PASMCs. First, the expression pattern of miR-1181 was characterized under PDGFBB treatment, and PDGF receptor/PKCβ signaling was found to repress miR-1181 expression. Then, gain- and loss-of-function experiments were respectively conducted and revealed the prominent role of miR-1181 in inhibiting PASMC proliferation and migration. Flow cytometry analysis suggested that miR-1181 regulated the PASMC proliferation through influencing the cell cycle transition from G0/G1 to S phase. Moreover, we exhibited that miR-1181 targeting STAT3 formed a regulatory axis to modulate PASMC proliferation. Finally, serum miR-1181 expression was also observed to be reduced in adult and newborn patients with PAH. Overall, this study provides novel findings that the miR-1181/STAT3 axis mediated PDGFBB-induced dysfunction in human PASMCs, implying a potential use of miR-1181 as a therapeutic and diagnostic candidate for the vascular remodeling diseases.
Keyphrases
- cell proliferation
- long non coding rna
- long noncoding rna
- cell cycle
- poor prognosis
- pulmonary arterial hypertension
- pulmonary artery
- growth factor
- pulmonary hypertension
- signaling pathway
- coronary artery
- transcription factor
- oxidative stress
- single cell
- risk assessment
- angiotensin ii
- smooth muscle
- binding protein
- drug induced
- pluripotent stem cells
- replacement therapy